Market research
G1H.F G1 Therapeutics, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 339M
- P/E ratio
- Not available
- Analyst target
- 50.86
- Dividend yield
- Not available
- Beta
- 1.68
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US3621LQ1099
- Market cap
- 339M
- P/E ratio
- Not available
- Analyst target
- 50.86
- Dividend yield
- Not available
- Beta
- 1.68
About
About G1 Therapeutics, Inc
G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the G1H.F discussion.
5 years, 5 months ago
G1 Therapeutics, Inc is currently in a long term uptrend where the price is trading 0.4% above its 200 day moving average.
From a valuation standpoint, the stock is 98.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 20.0.
G1 Therapeutics, Inc's total revenue rose by inf% to $17M since the same quarter in the previous year.
Its net income has increased by 28.5% to $-25M since the same quarter in the previous year.
Finally, its free cash flow fell by 1.3% to $-32M since the same quarter in the previous year.
Based on the above factors, G1 Therapeutics, Inc gets an overall score of 4/5.